May 30, 2025 Newswires

Jeonbuk National University Medical School Reports Findings in Type 2 Diabetes (Association of peripheral neuropathy with dementia in type 2 diabetes: a 5-year follow-up study using the national health insurance service-national health …): Nutritional and Metabolic Diseases and Conditions – Type 2 Diabetes

Information Technology Business Daily

2025 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes is the subject of a report. According to news reporting out of Jeonju, South Korea, by NewsRx editors, research stated, “To investigate whether the incidence of dementia is associated with diabetic peripheral neuropathy (DPN) in type 2 diabetes. Using the National Health Insurance Service-National Health Information Database, we calculated the incidence of various types of dementia according to type 2 diabetes with or without DPN by applying multivariate Cox regression analysis.”

Our news journalists obtained a quote from the research from Jeonbuk National University Medical School, “Propensity score matching was performed to equalize each group by considering demographic characteristics and underlying conditions. The incidence of various types of dementia was higher in patients with type 2 diabetes than in those without diabetes. The risk of developing dementia was higher in type 2 diabetes with DPN than in type 2 diabetes without DPN, irrespective of dementia type (all dementia: 1.53 vs. 2.1 vs. 1.4, P< 0.05, Alzheimer’s disease: 1.46 vs. 1.98 vs. 1.34, P< 0.05, vascular dementia: 1.86 vs. 2.75 vs. 1.66, P< 0.05, other dementia: 1.62 vs. 2.19 vs. 1.48, P< 0.05; all type 2 diabetes vs. type 2 diabetes with DPN vs. type 2 diabetes without DPN compared with non-diabetes). When sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were used, the incidence of all dementia types was lower in patients with type 2 diabetes than in patients with type 2 diabetes who did not use SGLT2Is although the incidence showed more decreased trend when dipeptidyl peptidase IV inhibitor (DPPIVI) was combined (all dementia: 0.51-0.71, P< 0.05, Alzheimer’s disease: 0.78-0.80, P< 0.05, vascular dementia: 0.28-0.35, P< 0.05, other dementia: 0.2-0.70, P< 0.05; SGLT2Is user vs. neither SGLT2I nor DPPIVI). This pattern was also observed in patients with type 2 diabetes and DPN (all dementia: 0.32-0.56, P< 0.05, Alzheimer’s disease: 0.44-0.55, P< 0.05, vascular dementia: 0.33, P< 0.05, other dementia: 0.53, P< 0.05; SGLT2Is user vs. neither SGLT2I nor DPPIVI).”

According to the news editors, the research concluded: “More active diagnostic and prevention efforts are needed to address the risk of developing all forms of dementia, including vascular dementia, in patients with diabetes and DPN.”

This research has been peer-reviewed.

For more information on this research see: Association of peripheral neuropathy with dementia in type 2 diabetes: a 5-year follow-up study using the national health insurance service-national health information database. Endocrine, 2025. Endocrine can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Endocrine - http://www.springerlink.com/content/1355-008x/)

Our news journalists report that additional information may be obtained by contacting Ko Woon Kim, Dept. of Neurology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, South Korea. Additional authors for this research include Heung Yong Jin, Kyung Ae Lee, Tae Sun Park, Min Ji Kim and Jong Seung Kim.